Two patients who developed refractory sclerodermatous cGVHD following allo-SCT received imatinib mesylate at the dose of 400 mg/day. In both patients, the scleroderma symptoms disappeared within ...
Twelve-week-old male ApoE−/− mice (10 mice per group) received vehicle control, Nilotinib (2 × 37.5 mg/kg/day orally) or Imatinib (2 × 50 mg/kg/day orally) and a hyper-lipid diet for 8 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback